NCT06083961 is a Phase 4 clinical trial of Alirocumab in Stroke, Acute Ischemic, sponsored by Sun U. Kwon.

Who is sponsoring NCT06083961?

NCT06083961 is sponsored by Sun U. Kwon.

What drugs are being tested in NCT06083961?

Interventions in NCT06083961: Alirocumab.

What condition does NCT06083961 study?

NCT06083961 studies Stroke, Acute Ischemic, PCSK9 Inhibitor.

Is NCT06083961 still recruiting?

NCT06083961 is currently not yet recruiting. Last updated 16 October 2023.

Last reviewed 2023-10-16 · How we verify

NCT06083961

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile

Not yet recruiting Phase 4 Last updated 16 October 2023

What this trial tests

Phase 4 trial testing Alirocumab in Stroke, Acute Ischemic in 200 participants. Not yet recruiting.

Timeline

15 October 2023

Primary endpoint
15 October 2026

15 November 2026

Quick facts

Lead sponsor	Sun U. Kwon
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	15 October 2023
Primary completion	15 October 2026
Estimated completion	15 November 2026
Sites	1 location across South Korea

Drugs / interventions tested

Alirocumab (ALIROCUMAB) — full drug profile →

Conditions studied

Stroke, Acute Ischemic — all drugs for Stroke, Acute Ischemic →
PCSK9 Inhibitor — all drugs for PCSK9 Inhibitor →

Sponsor

Sun U. Kwon

Who can join

19 and older, any sex, with Stroke, Acute Ischemic or PCSK9 Inhibitor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors) in acute ischemic stroke patients associated with atherosclerosis by investigating 1. the change in lipid profile compared to baseline results 2. the effects on prognosis of stroke The participants will be given PCSK9 inhibitor right after confirmation of acute ischemic stroke, and the investigators will compare the results to the control group, whom are acute ischemic stroke patients treated with conventional lipid lowering therapy, statin and/or ezetimibe.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke.
Zhou L, Zhang H, Wang S, Zhao H, et al · · 2023 · cited 3× · PMID 38273837 · DOI 10.3389/fphar.2023.1327185

Verify or expand the search:

Other trials of Alirocumab

Trials testing the same drug.

NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
NCT06385262 — TOP 2301: Neoadjuvant Chemo for NSCLC · Phase 2 · suspended
NCT06080256 — Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS) · Phase 3 · unknown
NCT06052020 — Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study · unknown

Other recruiting trials for Stroke, Acute Ischemic

Currently open trials in the same condition.

NCT06987305 — Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window · Phase 3 · recruiting
NCT06768138 — Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke · Phase 3 · recruiting
NCT06388148 — Endovascular Treatment for eXtra-Large Ischemic Stroke · NA · recruiting
NCT06374667 — The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Larg · NA · recruiting
NCT06010641 — Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06083961 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun U. Kwon
Last refreshed: 16 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06083961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing